Compare LAC & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | BBNX |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 997.9M |
| IPO Year | 2023 | 2025 |
| Metric | LAC | BBNX |
|---|---|---|
| Price | $2.64 | $19.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $6.14 | ★ $23.80 |
| AVG Volume (30 Days) | ★ 8.9M | 1.3M |
| Earning Date | 05-14-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $2.66 | $8.80 |
| 52 Week High | $10.52 | $32.71 |
| Indicator | LAC | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 47.73 |
| Support Level | N/A | $12.45 |
| Resistance Level | $3.31 | $20.48 |
| Average True Range (ATR) | 0.11 | 1.68 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 0.00 | 48.07 |
Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.